Clinical trials: Pneumonia, Interstitial
- Condition Pneumonia, Interstitial
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Idiopathic Interstitial Pneumonias / Hypertension,Pulmonary
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
To evaluate the efficacy and safety of 26-weeks of treatment with riociguat vs. placebo in patients with symptomatic PH (pulmonary hypertension) associated with IIP (idiopathic interstitial pneumonias).
- Trial name
- RISE-IIP (NCT02138825)
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- 93 sites in United States, Argentina and 19 more
- Volunteers
- 147 people
- Sponsor
- Bayer
Pulmonary Fibrosis
A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis
The purpose of this study is to provide an initial evaluation of the effectiveness of BMS-986278 in participants with lung fibrosis, to demonstrate the safety of BMS-986278, and provide information on the drug levels of…
- Trial name
- NCT04308681
- Testing
- BMS-986278
- Where
- 119 sites in United States, Argentina and 16 more
- Volunteers
- 403 people
- Sponsor
- Bristol-Myers Squibb
Idiopathic Pulmonary Fibrosis, Fibrosis
A Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis
This is a Phase 2, multicenter, multinational, randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, pharmacokinetics (PK), quality of life and exploratory pharmacodynamics (PD) of two treatment…
- Conditions
- Idiopathic Pulmonary Fibrosis, Fibrosis, Idiopathic Interstitial Pneumonias, Pathologic Processes
- Trial name
- NCT03142191
- Testing
- CC-90001
- Where
- 112 sites in United States, Australia and 11 more
- Volunteers
- 138 people
- Sponsor
- Celgene
COVID-19
A Phase 2 Study of APX-115 in Hospitalized Patients With Confirmed Mild to Moderate COVID-19.
This phase 2 study is to assess the safety and tolerability of APX-115 active doses compared to placebo following multiple oral dosing in hospitalized patients with confirmed, mild to moderate, symptomatic COVID-19.
- Trial name
- NCT04880109
- Testing
- APX-115
- Where
- 6 sites in United States
- Volunteers
- 16 people
- Sponsor
- Aptabio Therapeutics, Inc.
Covid19, Post-acute COVID-19 Respiratory Disease
LYT-100 in Post-acute COVID-19 Respiratory Disease
This study is being conducted in two parts, A and B. Part A is a randomized, double-blind, parallel arm study to evaluate the safety and efficacy of LYT-100 compared to placebo in adults with post-acute COVID-19 respiratory…
- Trial name
- NCT04652518
- Testing
- LYT-100
- Where
- 31 sites in United States, Argentina and 6 more
- Volunteers
- 185 people
- Sponsor
- PureTech
Idiopathic Pulmonary Fibrosis
Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
This is a Phase 3 trial to evaluate the efficacy and safety of 30 milligrams (mg)/kilogram (kg) intravenous (IV) infusions of pamrevlumab administered every 3 weeks as compared to placebo in participants with Idiopathic Pulmonary…
- Trial name
- NCT04419558
- Testing
- Pamrevlumab
- Where
- 157 sites in United States, Argentina and 23 more
- Volunteers
- 372 people
- Sponsor
- Kyntra Bio
Idiopathic Pulmonary Fibrosis
Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
To evaluate the safety and tolerability of pamrevlumab in participants with IPF, and the efficacy of pamrevlumab in slowing the loss of forced vital capacity (FVC) and the progression of IPF in these participants.
- Trial name
- NCT01890265
- Testing
- Pamrevlumab, Sub-Study: Pirfenidone, Sub-Study: Nintedanib
- Where
- 42 sites in United States, Australia and 5 more
- Volunteers
- 160 people
- Sponsor
- Kyntra Bio
Idiopathic Pulmonary Fibrosis
A 2-Part, Phase 2 Open-label and Crossover Study of Belumosudil for Treatment of Idiopathic Pulmonary Fibrosis
This Phase 2 study is to be conducted to evaluate the safety, tolerability, and activity of 400 mg of belumosudil orally (PO) once-daily (QD) compared to Best Supportive Care (BSC) in male and postmenopausal/surgically sterilized…
- Trial name
- NCT02688647
- Testing
- Belumosudil, BSC
- Where
- 10 sites in United States
- Volunteers
- 76 people
- Sponsor
- Kadmon Corporation, LLC
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT
This study assesses the safety and efficacy of bardoxolone methyl relative to placebo in patients with pulmonary hypertension to determine the recommended dose range, evaluate the change from baseline in 6-minute walk distance…
- Conditions
- Pulmonary Arterial Hypertension, Pulmonary Hypertension, Interstitial Lung Disease, Idiopathic Interstitial Pneumonia
- Trial name
- NCT02036970
- Testing
- Bardoxolone methyl
- Where
- 32 sites in United States, Germany
- Volunteers
- 166 people
- Sponsor
- Biogen
Lip Augmentation, Lip
RHA® 3 Versus Restylane-L® for Lip Augmentation
This is a multicenter, double-blinded, randomized, prospective, controlled clinical study to identify whether RHA® 3 is non-inferior to Restylane-L® for lip augmentation at Week 12 after the last treatment (initial or touch-up).
- Trial name
- NCT04540913
- Testing
- RHA 3, Restylane-L
- Where
- United States
- Volunteers
- 202 people, healthy volunteers welcome
- Sponsor
- Teoxane SA
Idiopathic Pulmonary Fibrosis
Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
This is a Phase 3 trial to evaluate the efficacy and safety of 30 milligrams (mg)/kilogram (kg) intravenous (IV) infusions of pamrevlumab administered every 3 weeks as compared to placebo in participants with IPF.
- Trial name
- NCT03955146
- Testing
- Pamrevlumab
- Where
- 125 sites in United States, Argentina and 7 more
- Volunteers
- 393 people
- Sponsor
- Kyntra Bio